A groundbreaking immunotherapy is showing unprecedented success against one of the deadliest childhood brain cancers — ...

Merck seems to have identified cytokines as a fertile ground for exploration, as the Synthekine deal follows its earlier $1.9 billion takeover of Pandion Therapeutics, which is developing a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated ... dose of FT596 was not reached, and cytokine release syndrome (CRS) was reported ...

The most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS ... used to manage CRS associated ...

This sensitized other dendritic cells and macrophages in the tumor environment to topical imiquimod therapy, which inhibited the formation of new blood vessels via the cytokine IL12 leading to the ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense challenge for patients, managing the emotional, logistical and personal burdens ...

Cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy guidelines.

Moreover, patients who had undergone prior CD19-directed CAR T-cell therapy had a complete response ... causing graft-versus-host disease, severe cytokine release syndrome, or immune effector ...